Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

Lung Cancer Clinical Trial

Official title:

Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06017271
• Other study ID #: XJTU1AF2023LSK-269
• Status: Not yet recruiting
• Start date: September 30, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: March 2023
• Source: First Affiliated Hospital Xi'an Jiaotong University
• Contact: Yang Yan
• Phone: 13259882601
• Email: yangyan3[@]xjtu.edu.cn
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The occurrence and progression of lung cancer is related to visceral adipose tissue (VAT). Epicardial adipose tissue (EAT) is a kind of VAT, producing a variety of inflammatory cytokines and adipokines, participating in the formation of local inflammation, promoting the formation of pre-thrombotic state, and leading to the occurrence of thromboembolism. Patients with lung cancer have increased inflammatory response and are more prone to suffer thrombosis. However, in lung cancer patients, the clinical correlation between EAT and pulmonary embolism has not been reported. Objective: To analyze the risk factors of poor prognosis in lung cancer patients with PE, and to explore the predictive value of EAT in pulmonary embolism events and death in lung cancer patients. Methods: EAT volume and density, as well as anthropometric and blood biomarkers, were evaluated in a sample of lung cancer patients, half with pulmonary embolism and half without. The incidence of adverse prognosis and related factors were followed up by telephone.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: June 30, 2024
• Est. primary completion date: October 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• The pathological diagnosis was lung cancer

• Pulmonary artery was evaluated by CTA during hospitalization.

Exclusion Criteria:

• Patients with incomplete clinical data

• Patients with no follow-up data

• Patients with a history of PE before diagnosis of lung cancer

Related Conditions & MeSH terms

• Embolism
• Lung Cancer
• Lung Neoplasms
• Pulmonary Embolism

Intervention

Diagnostic Test:
• CTPA (computed tomography pulmonary angiography)
The CTPA diagnosis suggest or did not suggest pulmonary embolism.

Locations

Country	Name	City	State
China	First Affiliated Hospital of Xian Jiaotong University	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
First Affiliated Hospital Xi'an Jiaotong University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	EAT volume	volume of epicardial adipose tissue (EAT), Cm3	May, 20, 2023
Primary	EAT density	density of epicardial adipose tissue (EAT) , Hounsfield Units (HU)	May, 20, 2023